These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 25414048

  • 1. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G.
    Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Real-life use of oral disease-modifying treatments in Austria.
    Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR).
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [Abstract] [Full Text] [Related]

  • 4. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH, Wakefield RA.
    Am J Health Syst Pharm; 2015 Jan 01; 72(1):25-38. PubMed ID: 25511835
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D, Nicholas J, Carraro M, Zhou J, Hou Q, Babb J, Riester K, Mendoza JP, Livingston T, Jhaveri M.
    Mult Scler Relat Disord; 2019 Jan 01; 27():101-111. PubMed ID: 30368221
    [Abstract] [Full Text] [Related]

  • 11. Oral agents in multiple sclerosis.
    Lorefice L, Fenu G, Frau J, Coghe GC, Marrosu MG, Cocco E.
    Antiinflamm Antiallergy Agents Med Chem; 2015 Jan 01; 14(1):15-25. PubMed ID: 25924620
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B, Pellkofer H, Weber MS.
    Curr Neurol Neurosci Rep; 2016 Apr 01; 16(4):38. PubMed ID: 26944956
    [Abstract] [Full Text] [Related]

  • 14. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
    Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y, SFSEP and OFSEP groups.
    Neurology; 2019 Aug 13; 93(7):e635-e646. PubMed ID: 31300547
    [Abstract] [Full Text] [Related]

  • 15. Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
    Papadopoulos D, Mitsikostas DD.
    CNS Drugs; 2018 Nov 13; 32(11):1069-1078. PubMed ID: 30069684
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.
    Curr Med Res Opin; 2014 Apr 13; 30(4):613-27. PubMed ID: 24195574
    [Abstract] [Full Text] [Related]

  • 17. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A.
    Pharmacol Res; 2017 Jun 13; 120():279-293. PubMed ID: 28396093
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
    Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M, Cohan S.
    J Comp Eff Res; 2019 Apr 13; 8(5):305-316. PubMed ID: 30754997
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.